USANA HEALTH SCIENCES INC
Close on Oct 19, 2026
- Market cap
- $275.26M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jul 4, 2026 | Aug 4, 2026 | After market close | $223.00M | $-1.16 | $-0.07 |
| Q1 FY2026 Ended Apr 4, 2026 | May 5, 2026 | After market close | $250.00M | $0.41 | $0.61 |
| Q4 FY2025 Ended Jan 3, 2026 | Feb 18, 2026 | After market close | $226.20M | $-0.10 | $0.60 |
| Q3 FY2025 Ended Sep 27, 2025 | Oct 9, 2025 | After market close | $214.00M | $-0.36 | $-0.15 |
| Q2 FY2025 Ended Jun 28, 2025 | Jul 22, 2025 | After market close | $236.00M | $0.52 | $0.74 |
| Q1 FY2025 Ended Mar 29, 2025 | Apr 22, 2025 | After market close | $250.00M | $0.49 | $0.73 |
| Q4 FY2024 Ended Dec 28, 2024 | Feb 25, 2025 | After market close | $214.00M | $0.23 | $0.64 |
| Q3 FY2024 Ended Sep 28, 2024 | Oct 22, 2024 | After market close | $200.00M | $0.56 | – |
| Q2 FY2024 Ended Jun 29, 2024 | Jul 23, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 30, 2024 | Apr 30, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 30, 2023 | Feb 6, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Oct 24, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | Fiscal Year 2026 | $87.00M | Lowered |
| Adjusted diluted EPSnon-GAAP | Fiscal Year 2026 | $0.76 | Lowered |
| Diluted EPSGAAP | Fiscal Year 2026 | $-0.61 | Lowered |
| Net (loss) earningsGAAP | Fiscal Year 2026 | -$11.00M | Lowered |
| Core Nutritional business net sales | Fiscal Year 2026 | $750.00M | Raised |
| Hiya net sales | Fiscal Year 2026 | $125.00M | Lowered |
| Rise Wellness net sales | Fiscal Year 2026 | $35.00M | Lowered |
| Consolidated net sales | Fiscal Year 2026 | $910.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Usana Health Sciences filed with the SEC
USANA Health Sciences Reports Second Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. August 4, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports First Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. May 5, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. February 17, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Kevin Guest Returns to USANA Health Sciences as CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. October 22, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Provides Preliminary Third Quarter Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. July 22, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. April 22, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. February 25, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Strategic Acquisition of Hiya Health
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Hiya Health | Acquisition Overview NYSE: USNA December 2024
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports Third Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. October 22, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports Second Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. July 23, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports First Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. April 30, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q 4 2023 Management Commentary
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports Third Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences, Inc. October 24, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Reports Second Quarter Net Sales of $238 Million and Diluted EPS of $0.89
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Key Financial & Operating Results
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Announces Plans to Expand into India
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
USANA Health Sciences Reports First Quarter Net Sales of $248 Million and Diluted EPS of $0.95
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Announces CEO Transition Plan
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Key Financial & Operating Results
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
USANA Health Sciences Provides Preliminary Fiscal Year 2022 Results and Issues Initial Fiscal Year 2023 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
USANA Health Sciences Reports Third Quarter Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Key Financial & Operating Results
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K